Company intelligence / Profile preview

HopeAI

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

HopeAI is an AI-powered clinical development platform company that has demonstrated the ability to reduce clinical timelines by up to 2.5 years, reduce Phase 3 trial sample sizes by up to 20%, and respond to FDA feedback within 24 hours. The company has validated its platform through commercial partnerships with two top 10 pharmaceutical companies and has conducted successful work on MRD (minimal residual disease) negativity association with survival endpoints in multiple myeloma[1][5].

Therapeutic areas: Oncology
Industry: Drug Discovery Services

Partnerships

Mayo Clinic Platform AccelerateHemOnc.orgTwo of the world's top 10 pharmaceutical companies (names undisclosed)Several innovative biotech companiesFred Hutch Cancer CenterTakeda

Beyond the preview

Go deeper on HopeAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HopeAI.

Explore the full profile